Candida glabrata Esophagitis: Are We Seeing the Emergence of a New Azole-Resistant Pathogen?
Background. Candida glabrata (C. glabrata) has become a recognized pathogen in fungal esophagitis. A proportion of these isolates are azole-resistant which may have treatment implications. Variability in the prevalence of this organism exists in the limited data available. Objective. To determine th...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2014-01-01
|
| Series: | International Journal of Microbiology |
| Online Access: | http://dx.doi.org/10.1155/2014/371631 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849686977864007680 |
|---|---|
| author | Aze Wilson Johan Delport Terry Ponich |
| author_facet | Aze Wilson Johan Delport Terry Ponich |
| author_sort | Aze Wilson |
| collection | DOAJ |
| description | Background. Candida glabrata (C. glabrata) has become a recognized pathogen in fungal esophagitis. A proportion of these isolates are azole-resistant which may have treatment implications. Variability in the prevalence of this organism exists in the limited data available. Objective. To determine the incidence of C. glabrata esophagitis in a North American hospital setting and to highlight factors that may predispose patients to this condition. Methods. Patient charts were collected from January 1, 2009 to July 30, 2011. Any charts of patients identified as having esophagitis with a positive fungal culture were reviewed for the species of Candida and the presence of factors that would predispose them to esophageal candidiasis. Results. The prevalence of Candida esophagitis based on culture was 2.2% (37 subjects). C. glabrata was the 2nd most prevalent pathogen identified (24.3% or 9 subjects). Of the C. glabrata cohort, all patients had at least one factor predisposing them to candidiasis. Conclusion. C. glabrata esophagitis makes up a large portion of the candidal esophagitis seen in hospital. C. glabrata infections were associated with at least one risk factor for candidal infection. Given its resistance to azole-based therapy, this may have treatment implications for how candidal esophagitis is approached by the clinician. |
| format | Article |
| id | doaj-art-01e484e89d9442549ea36f03824212be |
| institution | DOAJ |
| issn | 1687-918X 1687-9198 |
| language | English |
| publishDate | 2014-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | International Journal of Microbiology |
| spelling | doaj-art-01e484e89d9442549ea36f03824212be2025-08-20T03:22:30ZengWileyInternational Journal of Microbiology1687-918X1687-91982014-01-01201410.1155/2014/371631371631Candida glabrata Esophagitis: Are We Seeing the Emergence of a New Azole-Resistant Pathogen?Aze Wilson0Johan Delport1Terry Ponich2Division of Clinical Pharmacology and Division of Gastroenterology, Department of Medicine, London Health Sciences Centre, Western University, University Campus, 339 Windermere Road, Room C9-101, London, ON, N6A 5W9, CanadaDepartment of Medical Microbiology, London Health Sciences Centre, Western University, Victoria Campus, 800 Commissioners Road E., Room B10-105, London, ON, N6A 5W9, CanadaDivision of Gastroenterology, Department of Medicine, London Health Sciences Centre, Western University, Victoria Campus, 800 Commissioners Road E., Room E1-317, London, ON, N6A 5W9, CanadaBackground. Candida glabrata (C. glabrata) has become a recognized pathogen in fungal esophagitis. A proportion of these isolates are azole-resistant which may have treatment implications. Variability in the prevalence of this organism exists in the limited data available. Objective. To determine the incidence of C. glabrata esophagitis in a North American hospital setting and to highlight factors that may predispose patients to this condition. Methods. Patient charts were collected from January 1, 2009 to July 30, 2011. Any charts of patients identified as having esophagitis with a positive fungal culture were reviewed for the species of Candida and the presence of factors that would predispose them to esophageal candidiasis. Results. The prevalence of Candida esophagitis based on culture was 2.2% (37 subjects). C. glabrata was the 2nd most prevalent pathogen identified (24.3% or 9 subjects). Of the C. glabrata cohort, all patients had at least one factor predisposing them to candidiasis. Conclusion. C. glabrata esophagitis makes up a large portion of the candidal esophagitis seen in hospital. C. glabrata infections were associated with at least one risk factor for candidal infection. Given its resistance to azole-based therapy, this may have treatment implications for how candidal esophagitis is approached by the clinician.http://dx.doi.org/10.1155/2014/371631 |
| spellingShingle | Aze Wilson Johan Delport Terry Ponich Candida glabrata Esophagitis: Are We Seeing the Emergence of a New Azole-Resistant Pathogen? International Journal of Microbiology |
| title | Candida glabrata Esophagitis: Are We Seeing the Emergence of a New Azole-Resistant Pathogen? |
| title_full | Candida glabrata Esophagitis: Are We Seeing the Emergence of a New Azole-Resistant Pathogen? |
| title_fullStr | Candida glabrata Esophagitis: Are We Seeing the Emergence of a New Azole-Resistant Pathogen? |
| title_full_unstemmed | Candida glabrata Esophagitis: Are We Seeing the Emergence of a New Azole-Resistant Pathogen? |
| title_short | Candida glabrata Esophagitis: Are We Seeing the Emergence of a New Azole-Resistant Pathogen? |
| title_sort | candida glabrata esophagitis are we seeing the emergence of a new azole resistant pathogen |
| url | http://dx.doi.org/10.1155/2014/371631 |
| work_keys_str_mv | AT azewilson candidaglabrataesophagitisareweseeingtheemergenceofanewazoleresistantpathogen AT johandelport candidaglabrataesophagitisareweseeingtheemergenceofanewazoleresistantpathogen AT terryponich candidaglabrataesophagitisareweseeingtheemergenceofanewazoleresistantpathogen |